In total, 39 of 88 (44.3%%) unique molecular alterations (n = 21 PIK3CA [53.9%], n = 13 NRAS [33.3%], n = 4 ALK [10.2%], and n = 1 EGFR [2.6%] molecular alterations) were identified at the resistance time point in 13 of 24 (54.2%) patients with NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.